Årsredovisning 2024

Fulltext

===== SIDA 1 =====

Annual Financial Report
18 February 2025
Annual Financial Report
AstraZeneca PLC (the Company) announced today the publication of its Annual Report and
Form 20-F Information 2024 (the Annual Report).
A copy of the Annual Report will be submitted to the National Storage Mechanism and will
shortly be available for inspection at 
http://data.fca.org.uk/#/nsm/nationalstoragemechanism
.
The Annual Report is also available on the Company's website 
www.astrazeneca.com
.
The Annual Report will be dispatched to shareholders in due course.
The Company's Annual General Meeting (AGM) will take place on 11 April 2025. The Notice
of AGM and Shareholders' Circular will be published and distributed to shareholders in due
course.
EXPLANATORY NOTE
For the purposes of complying with the Disclosure and Transparency Rules, the Annual Report
being submitted to the National Storage Mechanism contains the following regulated
information in unedited form:
-   the principal risks and uncertainties facing the Company;
-   the Directors' responsibility statement made in respect of the Financial Statements and
Directors' Report contained in the Annual Report; and
-   a statement regarding related party transactions.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that
focuses on the discovery, development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal &
Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's
innovative medicines are sold in more than 125 countries and used by millions of patients
worldwide. Please visit 
astrazeneca.com
 and follow the Company on social
media 
@AstraZeneca
.
Contacts
For details on how to contact the Investor Relations Team, please click 
here
. For Media
contacts, click 
here
.
 
Adrian Kemp
Company Secretary
AstraZeneca PLC
 
This
 
information
 
is
 
provided
 
by
 
RNS,
 
the
 
news
 
service
 
of
 
the
 
London
 
Stock
 
Exchange.
 
RNS
 
is
approved
 
by
 
the
 
Financial
 
Conduct
 
Authority
 
to
 
act
 
as
 
a
 
Primary
 
Information
 
Provider
 
in
 
the
United
 
Kingdom.
 
Terms
 
and
 
conditions
 
relating
 
to
 
the
 
use
 
and
 
distribution
 
of
 
this
 
information
may apply. For further information, please contact 
rns@lseg.com
 or visit 
www.rns.com
.